Cabaletta Bio (CABA) Other financing activities (2020 - 2025)
Cabaletta Bio (CABA) posted quarterly Other financing activities of -$183000.0 for Q3 2025, down 114.07% year-over-year from $1.3 million in Q3 2024, and down 192.89% quarter-over-quarter from $197000.0 in Q2 2025.
Analysis
Cabaletta Bio (CABA) Other financing activities (2020 - 2025) Analysis & Trends
Cabaletta Bio's Other financing activities history runs 6 years deep, the most recent figure standing at -$183000.0 for Q3 2025.
- In Q3 2025, Other financing activities fell 114.07% year-over-year to -$183000.0; the TTM figure through Dec 2025 stood at $14000.0 (down 99.02% YoY), while the FY2025 annual figure was $14000.0, down 99.02% from the prior year.
- Other financing activities for Q3 2025 stood at -$183000.0, down from $197000.0 in the prior quarter.
- The five-year high for Other financing activities was $2.3 million in Q4 2023, with the low at -$980000.0 in Q2 2024.
- The 5-year median for Other financing activities is $197000.0 (2025), against an average of $347909.1.
- The sharpest annual moves came in 2021 and 2023: Other financing activities slumped 11300.0% in 2021, then soared 798.04% in 2023.
- Cabaletta Bio's Other financing activities stood at -$448000.0 in 2021, then soared by 111.38% to $51000.0 in 2022, then jumped by 4388.24% to $2.3 million in 2023, then tumbled by 43.16% to $1.3 million in 2024, then tumbled by 114.07% to -$183000.0 in 2025.
- Business Quant data shows CABA's Other financing activities at -$183000.0 in Q3 2025, $197000.0 in Q2 2025, and $1.3 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cabaletta Bio | 522.26 Mn | 522.26 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 94,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 250,000.00 |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 1.23 Mn |
| Sep 30, 2023 | 239,000.00 |
| Jun 30, 2023 | 390,000.00 |
| Mar 31, 2023 | 458,000.00 |
| Dec 31, 2022 | 25,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Dec 31, 2021 | 60,000.00 |
| Sep 30, 2021 | 459,000.00 |
| Dec 31, 2020 | 4,000.00 |